Chemical compound
Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.[1]
It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms[2][3]
Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.[medical citation needed]
Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache.[4][5][6][7][8] However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.[1]